Dr. Reddy’s Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market

October 3, 2020 team World Comments Off on Dr. Reddy’s Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. October 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Sensipar brand and generic market had U.S. sales of approximately $­­­­­312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*. Dr. Reddy’s Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

Please see for full prescribing information. https://www.drreddys.com/pi/cinacalcet-tabs.pdf
Sensipar is a trademark of Amgen Inc. *IQVIA Retail and Non-Retail MAT July 2020 RDY-0920-319

Related Articles

Business

Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets

October 6, 2020 team Business Comments Off on Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets

Hyderabad, India, October 5, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third […]

Business

Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

July 15, 2020 team Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. July 14, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch […]